Article Text

Download PDFPDF

PR087/#201  Prevalence of high-risk HPV DNA in a semi-urban population of uttarakhand, India using a point-of-care test
Free
  1. Shalini Rajaram1,
  2. Shilpa Panta2,
  3. Ayush Heda1,
  4. Ajeet Singh Bhadoria3,
  5. Latika Chawla4,
  6. Himani Bhan2,
  7. Varsha Kamath4,
  8. Nevetha Ravichandran4 and
  9. Jaya Chaturvedi4
  1. 1AIl India Institute of Medical Sciences, Rishikesh, Gynecologic Oncology (Obstetrics and Gynecology), Rishikesh, India
  2. 2AllMS Rishikesh, Obgyn, Rishikesh, India
  3. 3AllMS Rishikesh, Community and Family Medicine, Rishikesh, India
  4. 4AIl India Institute of Medical Sciences, Rishikesh, Obstetrics and Gynecology, Rishikesh, India

Abstract

Introduction WHO recommends a framework shift from screening with cytology and visual inspection methods, to detection of HPV DNA as the primary screening test and, endorses vaginal self-sampling as method of collection. This study was planned with the objective to determine the prevalence of HR-HPV 16/31 & 18/45 in vaginal samples using a real-time micro-PCR analyzer and to study the acceptability of self-sampling.

Methods Micro-PCR test (Truenat®) was used on vaginal samples collected by self-sampling for detection of HR-HPV infections 16/31,18/45. A sample size of 975 women was calculated with 95% confidence, 20% relative precision and adjusting for 10% non-responder rate. Samples were collected in the community during Covid-19 pandemic. Prevalence of HR-HPV 16,18 was determined separately by RT-PCR using HPV-Q Real-time PCR kit (genes2me).

Results Of 975 eligible women screened, prevalence was 4.6% with 45 women testing positive for HR-HPV (16/31,18/45). Of these 60% were confirmed positive for HR-HPV 16 & 18 by RT-PCR. Of the 45 positive women, 22(48.9%) underwent colposcopy and treated accordingly while the rest declined treatment. On studying acceptability of self-sampling, 943(96.72%) participants were ‘very satisfied’, 918(94.15%) found it to be ‘very comfortable’ and 863(88.51%) stated that they will strongly recommend it to other eligible women.

Conclusion/Implications HR-HPV testing with limited genotyping showed a prevalence of 4.6%, 60% of these were HPV 16/18 positive. Point of care testing was feasible in the community and self-sampling was acceptable. Roughly 50% declined treatment, and reasons need to be looked into.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.